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ABSTRACT
Glioblastoma multiforme (GBM) is the most common and fatal malignant adult 
primary brain tumor. Currently, the overall prognosis for GBM patients remains poor 
despite advances in neurosurgery and adjuvant treatments. MicroRNAs (miRNAs) 
contribute to the pathogenesis of various types of tumor, including GBM. In this study 
we analyzed the expression of a panel of miRNAs, which are known to be differentially 
expressed by the brain and GBM tumor, in a collection of patient-derived GBM stem-
like cells (GSCs). Notably, the average expression level of miR-135b, was the most 
downregulated compared to its normal counterpart, suggesting a potential role as 
anti-oncogene.
Restoration of miR-135b in GSCs significantly decreased proliferation, 
migration and clonogenic abilities. More importantly, miR-135b restoration was 
able to significantly reduce brain infiltration in mouse models of GBM obtained by 
intracerebral injection of GSC lines. We identified ADAM12 and confirmed SMAD5 
and GSK3β as miR-135b targets and potential mediators of its effects. The whole 
transcriptome analysis ascertained that the expression of miR-135b downmodulated 
additional genes driving key pathways in GBM survival and infiltration capabilities.
Our results identify a critical role of miR-135b in the regulation of GBM 
development, suggesting that miR-135b might act as a tumor-suppressor factor and 
thus providing a potential candidate for the treatment of GBM patients.
INTRODUCTION
Glioblastoma (GBM) is the most common and fatal 
malignant primary brain tumor in adults. Despite advances 
in treatment strategies combining surgery, radiotherapy 
and chemotherapy, the prognosis of patients remains poor, 
with a median survival time of approximately 12 to 14 
months. The extremely poor prognosis of GBM is largely 
due to the high tendency of invasion of the surrounding 
brain, incomplete surgical resection, and high frequency 
of tumor recurrence [1]. 
Growing evidence has led to the identification of a 
sub-population of tumor cells with stem-like properties, 
glioblastoma stem-like cells (GSCs), which specifically 
has a high capacity to resist or to adapt to standard 
therapies, leading to therapeutic resistance [2]. Thus, the 
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development of efficient therapies that are able to target 
these cells are urgently needed. The molecular mechanisms 
underlying the aggressive malignant phenotype of high 
grade glioma cells, are still largely unknown. However, 
the molecular characterization of GBM is unveiling new 
potential therapeutic strategies based on targeting specific 
components of oncogenic pathways, e.g., by delivering a 
therapeutic gene or microRNA (miRNA) [3-6]. Several 
miRNAs are differentially expressed in a variety of 
malignancies compared to corresponding healthy 
tissues. Some of these miRNAs have been shown to play 
important roles in cancer cell proliferation, aggressiveness 
and metastasis. Therefore, miRNAs might hold a great 
potential in the future treatment of GBM tumor. This 
prompted us to identify and to study miRNAs deregulated 
in GSCs isolated from GBM patients. 
In this report, we describe miR-135b as a miRNA 
that is significantly downregulated in GSCs compared 
to normal adult neural stem cells. The first evidence of a 
correlation between miR-135b and cancer emerged from 
a global miRNA expression profiling of microdissected 
tissues from pancreatic ductal adenocarcinoma (PDAC) 
patients that identified miR-135b as a novel biomarker 
for this tumor type [7]. Further studies revealed that 
dysregulation of miR-135b has a critical role in cancer 
progression. Particularly, the overexpression of miR-135b 
has been described in human head and neck squamous cell 
carcinoma (HNSCC) cell lines, where it causes increased 
cell proliferation, migration, and colony formation 
[8]; in human breast cancers, where it correlates with 
patient survival and early metastatization [9]; in highly 
invasive non-small-cell lung cancer cells where promotes 
cancer metastasis [10]. Moreover, miR-135b has been 
proposed as a biomarker and potential therapeutic target 
for colorectal cancer (CRC) and advanced adenoma 
[11]. Indeed, upregulation of this miRNA is common 
in sporadic and inflammatory bowel disease-associated 
human CRCs and correlates with tumor stage and poor 
clinical outcome [11]. miR-135b is frequently amplified 
and upregulated in hepatocellular carcinoma (HCC) 
and promotes HCC invasion and metastasis [12]. 
More recently, it has been demonstrated that miR-135b 
expression is frequently upregulated in osteosarcoma and 
promotes cell proliferation, migration and invasion [13]. 
In brain tumors miR-135b expression has been shown to 
be significantly higher in GBM compared to lower grade 
gliomas [14] as well as in frankly tumoral compared to 
peritumoral areas of GBM samples [15]. Altogether, these 
data strongly suggest that miR-135b behaves as an onco-
miRNA promoting tumor cells proliferation and invasion 
or as a key downstream effector of oncogenic pathways 
promoting tumor transformation and progression. In 
contrast to this view, we here describe that miR-135b is 
highly downregulated in our GSC line collection compared 
to their normal neural stem cells. More importantly, forced 
expression of miR-135b into GSCs markedly suppressed 
proliferation, motility and invasion of glioma cells as 
well as their stem cell-like phenotype through targeting 
ADAM12, SMAD5 and GSK3β. Furthermore, our data 
show that miR-135b inhibits glioma tumorigenesis and 
invasion in the brain of mice. This led us to assess the 
overall transcriptome changes upon enforced miR-135b 
expression in GSC lines, observing the modulation of 
transcripts belonging to additional pathways that play a 
relevant role in tumorigenesis. 
RESULTS
miR-135b expression is decreased in human GSC 
lines
In order to identify miRNAs relevant for GSC 
tumorigenesis, we analyzed by real time PCR a panel of 48 
miRNAs previously described as differentially expressed 
between normal and tumor tissue in GBM patients [16-
21], in a collection of GSC lines [22] compared with 
normal neural stem cell lines isolated from human adult 
olfactory bulb and foetal brain [23]. Among the miRNAs 
analyzed, 18 were detectable and dysregulated with at 
least a twofold variation compared to normal neural 
stem cells. The expression trend of 12 of them (i.e. miR-
21, miR-10b and miR-124) was in line with previously 
published results, whereas 2 miRNAs (miR-137 and miR-
218) showed an opposite trend [24]. The remaining 4 
miRNAs were invaluable due to insufficient or conflicting 
literature data.
miR-135b showed the most homogeneous profile in 
the GSC lines analyzed among the most downregulated 
miRNAs (Figure 1A). Being this observation apparently 
in contradiction with those published so far, we verified 
miR-135b expression in a larger panel of GSCs, as well as 
in the primary TB10, and commercially available T98G 
and U87MG, GBM cell lines (Figure 1B). Furthermore, a 
low expression of miR-135b was confirmed in a panel of 
16 GBM samples, 11 of which derived from patients that 
gave raise to GSC cultures (Supplementary Figure S1a, 
left panel). Compared to 4 normal brain tissues, derived 
from patient deceased for non oncological causes, GBM 
samples showed a slight but not significant increase of 
miR-135b expression, whereas GSCs, even though with 
a less homogeneous distribution, displayed a higher 
expression of miR-135b. Both GSCs and GBM samples, 
expressed lower level of miR-135b compared to normal 
neural stem cell reference. Interestingly, a similar behavior 
was observed for miR-21 (Supplementary Figure S1a, 
right panel), known to be upregulated in many tumors 
including GBM [17]. This observation may suggest that 
microenvironment may regulate miRNAs expression. 
Thus, to evaluate micro environmental effects on miR-
135b expression mouse xenogenic tumor by intracranial 
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and subcutaneous injection of GSCs were generated 
(Supplementary Figure S1b). Decreased miR-135b and 
miR-21 levels were observed in both xenograft models as 
compared to cultured tumor generating GSCs, indicating 
that microenvironment may contribute to miRNA 
regulation. However, we cannot exclude that cellular 
heterogenic composition of tumor tissue could account 
for the observed decrease of miR-135b and miR-21 levels 
in both xenograft models compared to cultured tumor 
generating GSCs.
To further confirm the data on miR-135b expression, 
we analyzed by In Situ Hybridization (ISH) a panel of 12 
GBM specimens and 4 normal brains derived from patients 
deceased for non oncological causes (Supplementary 
Figure S1c). Both patients and normal brains showed a 
highly heterogeneity of miR-135b expression ranging 
from complete negativity (Supplementary Figure S1c, 
panel D), few scattered positive cells (panel E) to more 
abundant positivity (panel C and F) with no significant 
differences between normal and GBM samples. Moreover, 
miR-135b expression in GBM samples was markedly 
lower than in colon adenocarcinoma used as the positive 
control (panel A). 
Figure 1: miR-135b is downregulated in GSC lines. A. Cell plot of expression values for several miRNAs (rows) in a cohort of 
GSCs and in 2 neural stem cell lines (columns, numbered). Ct values from real-time PCR were converted into relative abundance values 
and the scale ranges from low (green) to high (red). B. Expression of miR-135b detected by real-time PCR in a large collection of GSCs 
(grey), human neural adult (green) and fetal (blue) stem cells and GBM cell lines (purple). Relative expression values represent mean and 
SD from three independent experiments.
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Figure 2: miR-135b overexpression reduces cell growth, migration and clonogenic abilities of GSCs. A. Real-time PCR 
levels of miR-135b in GSCs non-transduced and transduced with either TRIPZ or TRIPZ-miR-135b inducible vectors after doxycycline 
exposure and in NS5 normal neural stem cell line. Values are mean and SD from at least three independent experiments in duplicate. B. 
Growth curves of individual GSCs (line number on top of each plot) transduced with either TRIPZ or TRIPZ-miR-135b vectors. Points 
and range lines at each day represent mean and SD of at least two independent experiments in triplicate. Two-way analysis of variance 
for repeated measures, performed on the whole set of data demonstrated a significant growth reduction by miR-135b in all GSCs (p = 
0.000167). C. Cell cycle phase distribution in TRIPZ and TRIPZ-miR-135b GSCs 6 days after induction. Representative values from 
three independent experiments are shown for each GSC line and are compared to the correspondent empty vector control. D. Analysis of 
migration efficiency in GSCs transduced with miR-135b 48h after induction. Values are reported as per cent relative to control vector and 
shown as mean ± SD from two independent experiments in duplicate. Analysis of variance demonstrated a significant effect of miR-135b 
restoration on the ability of GSCs to migrate (p < 0.0001). E. Analysis of efficiency in colony formation of GSCs after transduction with 
TRIPZ-miR-135b. Percent colony number values from two independent experiments in duplicate were calculated over the correspondent 
empty vector and are shown as mean ± SD for each GSC line. Analysis of variance demonstrated a significant effect of the presence of 
miR-135b on the colony-forming ability of GSCs (p < 0.0001).
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Restoration of miR-135b impairs tumorigenic 
properties of GSCs in vitro
To further investigate the role of miR-135b on GCS 
tumorigenic properties we over-expressed miR-135b in 
GSC lines by using an inducible Tet-On lentiviral vector 
(TRIPZ) carrying pri-miR-135b in the 3’ untranslated 
region of Red Fluorescent Protein (RFP). Seven GSC 
lines (#1, #30P, #61, #74, #83, #83.2 and #144P) chosen as 
representatives of different levels of miR-135b expression, 
were transduced and exposed to doxycycline. RFP-
positive cells were flow-sorted and miR-135b restoration 
was confirmed by real-time PCR (Figure 2A). All GSC 
lines transduced with this vector showed miR-135b 
expression levels comparable to normal cells or increased 
when compared to control vector (TRIPZ)-transduced 
cells. 
Ectopic expression of miR-135b significantly 
impaired cell growth of all the GSC lines tested (Figure 
2B), with a stable decrease in growth rate. To better 
characterized the inhibitory effect of miR-135b restoration 
on cell proliferation, we performed BrdU incorporation 
assay on 2 out of 7 cell lines, GSC #83, chosen as it shows 
the lowest ectopic expression of miR-135b, and GSC 
#144P, representative of the average levels achieved after 
transduction (Figure 2A). miR-135b significantly reduced 
BrdU incorporation in both cell lines independently of 
the levels of endogenous and restored miRNA expression 
(Supplementary Figure S2a) indicating a decreased 
progression in the cell cycle through the S phase.
We further evaluated DNA cell content in TRIPZ-
miR-135b- or empty vector- transduced GSCs (Figure 
2C) and found a consistent increase in the pre-G0 peak 
in most miR-135b-restored GSCs. Interestingly, in GSC 
#74, differently from the other transduced GSC lines, 
no increase of pre-G0 peak was found and a block in 
G2/M phase was observed, suggesting that miR-135b 
could inhibits tumor cell proliferation through different 
mechanisms. 
To deeply analyze the effect of miR-135b restoration 
on the induction of cell death we performed caspase 
3/7 activity evaluation on GSC line #83 and #144P. No 
significant induction of apoptosis was observed in both 
GSC lines (Supplementary Figure S2b) suggesting that 
overexpression of miR-135b is able to impairs GSC cell 
growth mainly by inhibiting cell proliferation rather than 
increasing apoptosis. 
We then examined whether miR-135b could alter 
additional malignant features of GSCs, such as migration. 
The motility of GSCs after miR-135b induction was 
examined and a dramatic reduction in the migration 
capabilities of TRIPZ-miR-135b GSCs (Figure 2D and 
Supplementary Figure S3), was observed.
Moreover, we analyzed the clonogenic capability 
of GSC expressing miR-135b. Doxycycline-induced cells 
were plated as single cells in 96 well plates in duplicate 
and allowed to grow for two weeks. TRIPZ-miR-135b 
GSCs formed significantly fewer colonies as compared 
to TRIPZ cells (Figure 2E). Thus, miR-135b restoration 
resulted in a considerable inhibition of proliferation, 
migration and colony formation of all the GSCs tested, 
suggesting that this miRNA could play a pivotal role in 
GBM oncosuppression.
To complement this set of experiments, endogenous 
miR-135b was inhibited in normal neural adult stem cells 
by transducing lentiviral vector carrying anti-sense miR-
135b or anti-sense control sequence and green fluorescent 
protein (GFP) as a reporter. After transduction a 40% 
decrease of the endogenous levels of miR-135b was 
observed in GFP-positive cells (Supplementary Figure 
S4a). miR-135b knockdown induced only minimal 
variations in either estimate stem cell frequency (32.4 
of anti-miR-135b vs 45.3 of NTC, p = 0.317), or BrdU 
incorporation (Supplementary Figure S4b) or migration 
(Supplementary Figure S4c). These results may be 
consistent with the relative small changes of miR-135b 
after knockdown of endogenous miR-135b.
miR-135b restoration significantly decreases in 
vivo tumor growth
To evaluate whether our findings were confirmed in 
vivo, the TRIPZ and the TRIPZ-miR-135b GSC lines #83 
and #144P were grafted into the striatum of NOD/SCID 
mice (Figure 3A). 
Tumor growth was assessed at 8 weeks after grafting 
during which mice received doxycycline in drinking 
water. Fluorescence microscopy analysis of serial coronal 
brain sections showed that the degree of brain invasion 
was significantly reduced in TRIPZ-miR-135b GSC 
brain xenografts (Figure 3B). Eight weeks after grafting, 
control TRIPZ grafted mice (n = 6) harbored tumors 
that invaded the homolateral striatum, piriform cortex, 
corpus callosum, anterior commissure, internal capsule, 
and fimbria-hippocampus, whereas the degree of brain 
invasion was significantly reduced in TRIPZ-miR-135b 
grafted mice (n = 6) (Figure 3C). In mice injected with 
GSC #83, the volume of the brain region invaded by the 
red fluorescent tumor cells was 2.597 ± 0.365 and 1.376 
± 0.187 mm3 (mean ± sem) in TRIPZ and TRIPZ-miR-
135b grafted mice, respectively (p = 0.041). A similar 
pattern was found in GSC #144P xenografts with invasion 
volumes of 2.172 ± 0.235 and 1.301 ± 0.194 mm3 (mean 
± sem) in TRIPZ and TRIPZ-miR-135b grafted mice, 
respectively (p = 0.046) (Figure 3C).
In order to better characterize the effect of miR-
135b restoration on tumor growth in vivo, we decided to 
set up two additional models by intracerebral injection 
of U87MG GBM cells and by subcutaneous injection of 
T98G GBM cells. As shown in Figure 1B, these cell lines 
express very low levels of miR-135b compared to normal 
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Figure 3: miR-135b overexpression reduces the in vivo growth of GSC-derived brain tumor. A. Representative coronal 
sections of the mouse brain illustrating the sites of cell injection (box A) and of brain invasion (box B). Mice were injected with two 
different GSC lines (#83 and #144P) transduced with either empty vector or miR-135b. B. Fluorescence microscopy images of mouse brain 
specimens at eight weeks after injection of GSC #83 (left panel; A, injection site; B, corpus callosum) and of GSC #144P (right panel; A, 
injection site; B, piriform cortex). C. Analysis of the extent of tumor cell mass in the full series of brain sections from mice injected with 
control and miR-135b-overexpressing GSCs.
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neural stem-like cells, consistent with the expression in 
the majority of GSC lines. TRIPZ and the TRIPZ-miR-
135b U87MG GBM line were grafted into the striatum of 
NOD/SCID mice. Twelve days after grafting, the brains 
injected with control U87MG cells (n = 5) showed the 
tumor growing along the needle tract from the cortex to 
the striatum and exerting a mass effect (Supplementary 
Figure S5, upper panel). In addition, spheroid aggregates 
of tumor cells were found in the ventricles, as a result of 
spreading along the cerebrospinal fluid paths. The tumor 
xenografts had intense proliferating activity, as assessed 
by DAPI staining and Ki67 immunoreaction, with mitotic 
index of 4.57 + 0.68 per cent (mean + SD). Conversely, 
the brains grafted with TRIPZ-miR-135b U87MG cells (n 
= 4) showed groups of fluorescent cells in the injected area 
that did not produced any mass effect on the surrounding 
brain parenchyma (Supplementary Figure S5, lower panel) 
and with no evidence of proliferating activity. Moreover, 
TUNEL assay did not show an increase of cell death in 
TRIPZ-miR-135b xenografts (data not shown) confirming 
that, as assessed in vitro, miR-135b exerts its function 
mainly by inhibiting proliferation than by inducing 
apoptosis. 
To confirm the effect of miR-135b restoration in 
tumor growth we chose subcutaneous grafting of GSCs 
as Matrigel implants in immunodeficient mice, a well 
suited model to study the early stages of in vivo tumor 
growth [25]. Histological examination showed that four 
weeks after grafting the implants (n = 3) were populated 
by cluster of tumor cells and that cell proliferation was 
lowered in TRIPZ-miR-135b T98G xenografts compared 
with paired TRIPZ T98G xenografts as assessed by 
immunostaining with anti-Ki67 (Supplementary Figure 
S6). 
Tumor-suppressor function of miR-135b involved 
ADAM12 and SMAD5 signaling
To further understand the molecular mechanism 
by which miR-135b can behave as tumor-suppressor, 
we tried to establish whether any of its putative targets 
might play a significant role in GBM biology. Most of 
the target genes identified by several target prediction 
engines shared a tumor-suppressor function compatible 
with the upregulation of this miRNA in most of the 
different cancers analyzed in previous studies. Since 
recent evidence supports the notion that miRNAs act on 
their target gene repertoire also at the transcriptional level 
affecting the transcript stability [26], we characterized at 
the transcriptome level the effects of miR-135b restoration 
in the context of GSC cell lines. To this end, we performed 
microarray analysis of RNA from TRIPZ and TRIPZ-
miR-135b GSC cell line #83. We expected higher effect 
of miR-135b restoration in this GSC line since it has the 
lowest expression of miR-135b. We hence examined the 
annotation for the most downregulated genes. A list of 
potential target mRNAs was obtained for miR-135b using 
TargetScan 6.2 algorithm (www.targetscan.org). Among 
these, the metalloproteinase ADAM12 is highly expressed 
in human GBM and might play a role in the prominent 
proliferation of tumor cells through shedding of heparin-
binding epidermal growth factor (HB-EGF) [27]. Another 
potential mediator of the tumor-suppressive ability of miR-
135b is SMAD5, which has been recently identified as one 
of the target of miR-135b activated by the transcription 
factor PAX6 [28]. Moreover, a third miR-135b target in 
GSCs could be GSK3β, whose downregulation has been 
involved in radioresistance acquisition of a U87MG GBM 
cell line derivative [29]. The comparison in GSCs between 
the expression of miR-135b and the protein level of the 
three targets showed an inverse correlation (Figure 4A and 
Supplementary Figure S7), thus supporting the hypothesis 
that ADAM12, SMAD5 and GSK3β are indeed miR-
135b targets in GSCs. To corroborate these results, we 
evaluated the expression of the three target proteins in 
TRIPZ and TRIPZ-miR-135b GSCs. We chose to assay 
the target protein levels two days after attaining full 
miRNA induction, in order to allow protein and transcript 
turnover to be affected by post-transcriptional repression. 
Results in Figure 4B show that ADAM12, SMAD5 and 
GSK3β target proteins are considerably diminished in 
cells after miR-135b is induced, albeit at different extent 
that might arise from differential affinity of the miRNA 
for the transcript, differential transcript/protein half-life or 
other factors.
To assess whether ADAM12 is a direct target of 
miR-135b, we cloned part of ADAM12 3’UTR into a 
luciferase reporter vector. Co-transfection in 293T, along 
with miR-135b mimic-oligonucleotide, significantly 
reduced the luciferase activity compared to a control 
oligonucleotide (scramble) (Supplementary Figure S8). 
The luciferase activity was restored in a construct bearing 
five mutations in the putative miR-135b target sequence 
(Supplementary Figure S8). These results strongly support 
a direct targeting of ADAM12 by miR-135b as previously 
demonstrated for the other two targets SMAD5 and 
GSK3β [28, 29].
Phenotype rescue is partially established through 
ADAM12 re-expression
ADAM12 is selectively expressed in GBM tissues 
[27] where it might be involved in supporting tumor 
cell proliferation that is mainly sustained by enhanced 
EGF signaling through EGFR. Heparin-binding EGF-
like growth factor (HBEGF), a known EGFR ligand 
produced as a transmembrane protein needing enzymatic 
cleavage to be active, is an ADAM12 substrate, and 
has been implicated in EGFR dysregulation [30]. To 
ascertain whether a decrease in ADAM12 mediates the 
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Figure 4: miR-135b overexpression induces a significant decrease in the level of target proteins. A. Normalized levels 
of miR-135b/U6 expression were plotted with protein levels of the three main miR-135b targets in a large cohort of GSCs, T98G GBM 
cell line and a representative normal neural stem cell line. Protein levels, normalized with β-actin, were determined relative to GSC #83.2 
showing the higher content of the three protein targets. Bars indicate the mean values ± SD of two independent experiments and show a 
significant inverse correlation among miR-135b and putative target levels (ADAM12 ρ = -0.635, p = 0.001; SMAD5 ρ = -0.484, p=0.022; 
GSK3β ρ = -0.447, p = 0.037). B. Representative western blot analyses of the three main miR-135b targets in a cohort of GSCs transduced 
with either TRIPZ vector or TRIPZ-miR-135b. Values below the miR-135b lanes indicate the fold change in protein levels relative to the 
TRIPZ control vector.
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oncosuppressor properties of miR-135b and to verify 
phenotype recovery, functional experiments were 
performed. TRIPZ- and TRIPZ-miR135b GSC #83 
and #144P were transduced with lentiviral constructs to 
restore ADAM12 target gene. Overexpression of ADAM 
12 was verified by immunoblotting (Figure 5A). The 
results shown in Figure 5B-5D support the hypothesis that 
ADAM12 contributes to the oncosuppressive properties 
of miR-135b, as its re-expression mitigates the decreased 
proliferation (Figure 5B), migration (Figure 5C) and 
clonogenic ability (Figure 5D) imparted by this miRNA.
Transcriptome changes associated with miR-135b 
expression
To gain further insight into the regulatory program 
of miR-135b in GSCs, we assessed the transcriptome 
variation upon miR-135b doxycycline-mediated induction. 
Microarray profiling allowed to find additional genes 
in the TGFβ pathway that are downmodulated in miR-
135b expressing cells, such as SMAD2 and TGFBR2 
(Supplementary Figure S9). A search for enrichment of 
modulated transcript in the KEGG pathways identified the 
cell adhesion molecules as the most statistically significant 
category to be modulated, being the only pathway enriched 
with all three scores under the 0.005 threshold (LS 
permutation p = 0.00008, KS permutation p = 0.00079, 
Efron-Tibshirani’s GSA test p < 0.005). Also, when the 
downregulated transcripts were analyzed for pathway 
enrichment through the web-based ConsensusPathDB 
[31], transcripts belonging to the extracellular matrix 
set emerged as the category more enriched. Indeed, we 
observed downmodulation of several transcripts belonging 
to members of the integrin and of the laminin family, with 
documented interactions among them and in the syndecan 
family (SDC4 and SDCBP), which can function as both 
interaction partners for integrins, and for facilitators in the 
action of membrane ligands such as FGF2 and EGF. We 
hypothesized that this decrease in proteins involved in cell/
extracellular matrix (ECM) interaction might contribute to 
the proliferation and migration inhibition exerted by miR-
135b both by diminishing integrin-mediated signaling and 
by reducing EGF and FGF2 effects.
DISCUSSION
Growing evidence has revealed that miRNAs play 
crucial roles in tumorigenesis, angiogenesis, invasion, and 
apoptosis in various types of tumor, including GBM [24]. 
It has been recently demonstrated that miRNA expression 
profiles are particularly useful for subclassification of 
GBM. Recent studies have shown that miRNAs could 
play a role in determining cancer stem cell properties, 
contribute to treatment resistance, and suggest that 
miRNAs are not only putative biological markers for 
diagnosis, but also one of the most promising target for 
GBM treatment [32]. Anyway, although several studies 
have tried to identify miRNA profile for GBM, a specific 
expression signature is not still well-defined due to 
discrepant results encountered in literature between GBM 
miRNA expression studies. These discrepancies could 
mainly be due to the adopted techniques to evaluate their 
expression, the source of neoplastic specimens and the 
choice of reference samples used in the analysis. It has 
been shown that it is more advisable to compare miRNA 
expression data within similar experimental conditions 
which, in particular, are strictly dependent on the non-brain 
neoplastic reference [33]. In line with this observation our 
results showed that a comparison between cultured cells 
and tumor tissues should be interpreted very carefully for 
several reasons including micro environmental factors that 
could regulate their expression. Thus, in this study, we 
decided to choose normal neural stem cell lines as control 
group to analyze miRNA expression in our collection of 
GSCs.
Here, we showed that miR-135b is downregulated 
in GSC lines and in commercial GBM cell lines, U87MG 
and T98G, compared to normal adult and fetal neural 
stem-like cells. The analysis of miR-135b expression in 
GBM tissue samples showed a slight but not significant, 
increase compared to normal brain tissue however, in both 
tissue samples, miR-135b levels were lower than in cell 
cultures. The expression of miR-135b in GSCs could be 
due to different mechanisms including the EGF machinery 
and microenvironment [34]. Xenograft experiments, 
indeed, showed that tumor generated by GSC injection 
expressed lower level of miR-135b than the parental cell 
line, comparable with GBM samples. 
Even though a pro-tumorigenic function has been 
described for miR-135b in different cellular systems, 
functional characterization of this miRNA in GSC 
showed a tumor suppressive behavior. Thus, restoration 
of miR-135b expression significantly impairs GSC 
tumorigenic ability in vitro and in vivo. We identified 
ADAM12 and confirmed SMAD5 and GSK3β as direct 
targets of miR-135b. GSK3β has recently been shown to 
be a crucial enzymatic regulator of a diverse number of 
cellular functions including cell structure, metabolism, 
and survival [35]. Although the role of GSK3β in the 
regulation of apoptosis is controversial, it has been 
recently demonstrated a role for GSK3β in mediating 
glioma cell proliferation arrest, decreased clonogenicity 
and induction of apoptotic cell death through both the 
extrinsic and intrinsic apoptotic pathways both in vitro 
and in vivo [36]. On the other hand, inhibition of GSK3β 
activity results in c-MYC dependent glioma cell death 
through multiple mechanisms, all of which converge 
on the apoptotic pathways. GSK3β may therefore be an 
important therapeutic target for gliomas [36-38].
One of the most common signaling changes in 
GBM is the aberrant activation of various receptor 
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Figure 5: ADAM12 re-expression in GSCs partly induces phenotypic rescue. A. Western blot analysis of ADAM12 on GSC 
lines #83 and #144P (TRIPZ and TRIPZ-miR-135b) transduced with either empty Tween vector or Tween-ADAM12. B. Growth curve of 
GSC lines #83 and #144P (TRIPZ and TRIPZ-miR-135b) expressing ADAM12 gene. Points and range lines at each day represent mean 
and SD of at least two independent experiments in triplicate. C. Percentage of migrating cells in GSC (TRIPZ and TRIPZ-miR-135b) after 
transduction with either Tween or Tween-ADAM12 vectors. Per cent values are reported as mean ± SD from two independent experiments 
in duplicate. D. Analysis of efficiency in colony formation of GSC (TRIPZ and TRIPZ-miR-135b) after transduction with Tween or Tween-
ADAM12 vectors. Data are expressed as means ± SD of two independent experiments performed in duplicate.
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tyrosine kinases [39]. In particular, EGFR receptor 
activation by either overexpression or mutation is a 
common oncogenic event in more than 50% of GBM 
[40]. EGFR signaling regulates the proliferation and 
tumorigenic ability of GSCs by inducing ID3 and ID3-
regulated cytokines (GRO1, IL-6, and IL-8), which 
play a crucial role to make the tumor microenvironment 
suitable for GSC maintenance. EGFR-mediated ID3 
expression is regulated by SMAD5, which is directly 
phosphorylated by AKT [41]. ADAM12 is a member of 
the Zn2+ dependent metalloproteinase superfamily, and is 
expressed as both membrane-bound and secreted enzyme. 
Overexpression of ADAM12 is implicated in the onset and 
progression of a number of disease conditions, including 
cancer [42]. Human ADAM12 exists in two forms that 
arise from alternative splicing; the prototype membrane-
anchored protein (ADAM12m) and the shorter secreted 
type form (ADAM12s) [43]. It has been demonstrated 
that ADAM12m is selectively expressed in GBM tissues 
and that its expression levels is directly correlated with 
MIB1-positive cell index of the malignant astrocytic 
tumors [27]. This suggests the possible involvement of 
ADAM12m in the proliferation of GBM that is mainly 
sustained by enhanced EGF signaling through EGFR. 
The membrane-bound form of EGF-like ligands has 
limited biological activity and must be cleaved in a 
process known as ectodomain shedding to become fully 
functional [44]. ADAM12 plays an important role in the 
regulation of ectodomain shedding, resulting in production 
of soluble growth factors [30]. Heparin-binding EGF-
like growth factor (HBEGF), a known EGFR ligand 
produced as a transmembrane protein needing enzymatic 
cleavage to be active, is an ADAM12 substrate, and has 
been implicated in EGFR dysregulation [30]. Moreover, 
growing evidences have indicated for ADAM12 an 
important role in supporting tumor cell adhesion, which 
is mediated through binding of the cysteine-rich domain 
of ADAM12 to syndecans, cell surface proteoglycans [45, 
46]. Because syndecans become expressed in the reactive 
astrocytes surrounding the region of the brain necrosis, it 
has been speculated that ADAM12 might facilitate GBM 
cells to attach to the reactive astrocytes present near 
the leading invasive edge or, alternatively, it might be 
involved in mutual cell attachment and spreading of GBM 
cells to form tumor cell aggregates that are commonly 
observed in human GBM during the invasive growth [27]. 
Syndecans and/or β1 integrin are required for ADAM12-
mediated cell attachment and spreading [45]. In line with 
this evidence, we observed that miR-135b expression 
is coupled to a significant decrease in the expression 
of SDC4 and β1 integrin transcripts, along with other 
ligands and receptors of the ECM. ADAM12 has potential 
to emerge as a successful drug target, although targeting 
the metalloproteinase domain with any specificity will be 
difficult to achieve due to structural similarity between 
the ADAM members and matrix metalloproteinase 
(MMP) family of enzymes. Moreover, since miRNAs 
can modulate simultaneous and distinct functions such as 
tumor growth, invasion, and angiogenesis in GBM, miR-
based therapies may prove more effective than current 
molecular-target therapies, which target single protein-
coding genes belonging to more complex oncogenic 
signaling pathway and achieve modest changes for more 
global gene expression. Our data on the role of miR-
135b in GBM along with recent progress in the delivery 
of functional miRNA molecules across the blood-brain 
barrier [47], reinforce the concept that molecular-targeting 
therapy based on miRNA expression in GSCs has the 
potential to allow more effective treatment strategies for 
this incurable type of cancer. 
MATERIALS AND METHODS
Cell cultures
Packaging cell line, 293T, were maintained in 
DMEM (Life Technologies Corporation, Carlsbad, CA) 
supplemented with 10% (v/v) heat-inactivated FBS, 2 
mM L-glutamine, 100 U/ml of penicilline and 100 µg/ml 
of streptomycin (Invitrogen). Glioblastoma stem-like cells 
were isolated from surgical samples of adult patients who 
had undergone craniotomy at the Institute of Neurosurgery, 
Catholic University of Rome, upon patient informed 
consent and approval by the local ethical committee. 
Surgical specimens were subjected to mechanical 
dissociation and the resulting cell suspension was cultured 
in a serum free medium supplemented with EGF and 
bFGF as previously described [22]. Cell lines actively 
proliferating required 3 to 4 weeks to be established. In 
these conditions, cells grew as clusters (neurospheres) of 
undifferentiated cells, as indicated by morphology and 
expression of stem cell markers such as CD133, SOX2, 
Musashi-1, and nestin. The in vivo tumorigenic potential 
of GBM neurospheres was assayed by intracranial or 
subcutaneous cell injection in immunocompromised mice. 
GBM neurospheres were able to generate tumors with 
the same expression and histological tissue organization 
as the human parent tumor. GSC lines were validated by 
Short Tandem Repeat (STR) DNA fingerprinting. Nine 
highly polymorphic STR loci plus amelogenin (Cell IDTM 
System, Promega Inc., Madison, WI) were used. Detection 
of amplified fragments was obtained by ABI PRISM 3100 
Genetic Analyzer (Applied Biosystems, Carlsbad, CA, 
USA). Data analysis was performed by GeneMapper® 
software, version 4.0 (Biological Bank and Cell Factory, 
National Institute for Cancer Research, IST, Genoa, Italy). 
All GSC line profiles were challenged against public 
databases to confirm authenticity. To assess clonogenicity, 
viable cells were dispensed at different densities (1, 3 
and 10 cells/well) in 96 well plates by cell sorting (FACS 
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Aria, Becton Dickinson). After 10-14 days, the wells 
with growing clones were enumerated, and results were 
analysed by the Extreme Limiting Dilution Assay (ELDA) 
software (http://bioinf.wehi.edu.au/software/elda/) [48]. 
Data concerning patients and GSCs are summarized in 
Supplementary Table S1. Human adult neural stem cell 
line, NS5, were isolated from human neural adult tissue 
obtained following the ethical guidelines of the NECTAR 
and the Declaration of Helsinki from patients undergoing 
particularly invasive neurosurgery as previously described 
[23]. Human neural progenitor cell (HNPC) lines were 
purchased by Lonza (Lonza Inc. Walkersville, MD, USA). 
Normal neural adult and fetal stem-like cell lines were 
cultured in the same serum free medium supplemented 
with EGF and bFGF used for GSC lines. The U87MG 
and T98G cell lines were purchased from ATCC and were 
cultivated in the recommended media (see www.atcc.org 
for details). The TB10 cell line was established in our 
laboratory from a human GBM tumor under conventional 
adherent culture with serum-containing medium [49].
Plasmid constructs and lentivirus infection
The miR-135b precursor was cloned in the 3’ 
untranslated (UTR) region of RFP in the pTRIPZ 
doxycycline inducible lentiviral vector (Thermo 
Fisher Scientific, Waltham, MA, USA). Primers 
used for pri-miRNA-135b amplification were: 
CGGTCTAGACCATTGTGTGAGGCCTTT (Forward) 
and CCCGATATCACCCCCCAAATCT (Reverse). 
miRZip™ anti-sense miR-135b and miRZip™ control 
(NTC) were purchased by SBI (System Biosciences Inc., 
Mountain View, CA, USA). For ADAM12 constitutive 
expression ADAM12 cDNA (NM 003474) was 
cloned into Tween lentiviral vector [23] by XbaI-Xho 
restriction enzime. Lentiviral particles were produced 
by the calcium phosphate transfection protocol in 293T 
packaging cell line and infection performed as previously 
described [23]. After infection transduced cells were 
selected with puromycin and Red Fluorescent Protein 
(RFP) fluorescence was evaluated by FACSCanto (BD 
Biosciences, Milan Italy) upon doxycycline induction 
(Sigma Aldrich Inc., Saint Louis, MO).
Real-time PCR
Total RNA was extracted from cells using TRIzol 
reagent (Life Technologies Corporation) and from 
microdissected paraffin embebbed GBM sections 
using miRNeasy FFPE kit (QIAGEN s.r.l., Milan Italy) 
Fifty nanograms of RNA were reverse transcribed with 
TaqMan MicroRNA Reverse Transcription Kit (Applied 
Biosystems). Real-time PCR for miR-135b (miRBase ID 
hsa -miR-135b-5p, v21) was performed using TaqMan® 
MicroRNA Assays protocol (assay ID 002261 Applied 
Biosystems). All reactions were run in duplicate. 
Normalization was performed by using RNU6B primer 
kit (ID 001093, Applied Biosystems). Relative expression 
was calculated with relative standard curves for miR-
135b and the endogenous control. RT-PCR analysis was 
performed using an ABI Prism 7900 Sequence Detector 
(Applied Biosystems).
In situ hybridization
In situ detection of miR-135b was performed 
on formalin fixed paraffin embedded GBM 
samples using miRCURY LNA microRNA 
ISH optimization kit (Exigon, Vedbaek 
Denmark) according to manufacturer’s instruction.
Cell growth, migration and colony formation
For the proliferation assay, TRIPZ and TRIPZ-miR-
135b GSCs were plated at density of 2x104/ml in 96 well 
plates in triplicate. Cell proliferation was monitored by 
counting the cells and confirmed by using the CellTiter-
Blue Viability Assay (Promega). Cell proliferation 
was also evaluated by Bromo-2’-deoxyuridine (BrdU) 
incorporation using BrdU Cell proliferation ELISA kit 
(colorimetric) (abcam, Cambridge, UK) according to 
manufacturer’s instruction. 
The motility of transduced GSCs was evaluated by 
plating in Corning FluoroBlokTM Multiwell Inserts System 
(Corning Life Sciences, Tewksbury, MA, USA), according 
to manufacturer’s instruction. Briefly, 2-3x103 GSCs 
were added to the upper chambers in stem cell medium. 
Growth factors (EGF and bFGF) added to the stem cell 
medium were used as chemoattractant in the lower wells. 
The plates were incubated for 48h at 37°C, after which 
the fluorescent dye calcein acetoxymethylester (calcein 
AM) was added to the lower chamber for 30 min. The cell 
viability indicator calcein AM is a non-fluorescent, cell 
permeant compound that is hydrolyzed by intracellular 
esterases into the fluorescent anion calcein and can be 
used to fluorescently label viable cells before microscope 
observation.
Colony formation ability was evaluated by plating 
a single cell/well in 96 well plates. After 3-4 weeks, 
each well was examined and the number of spheres/
cell aggregates were counted. All the experiments 
were performed in stem cell medium in the presence of 
doxycycline. 
Cell cycle assay and apoptosis
For cell cycle analysis 2x105 GSCs were 
mechanically dissociated and resuspended in Nicoletti’s 
buffer, containing 0,1% Sodium Citrate, 10mM NaCl, 
Oncotarget37253www.impactjournals.com/oncotarget
0,1% Triton X-100, 200mg/mL Propidium Iodide (PI) 
and 200 mg/mL RNAse A [50]. Following 30 min 
incubation at room temperature cells were acquired with a 
FACSCanto flow cytometer (BD Biosciences).
Apoptosis was evaluated using caspase 3/7 
activity detection. 2x104/ml in 96 well plates in triplicate 
and caspase activity was evaluated using Apo-ONE® 
Homogeneous Caspase-3/7 Assay (Promega) according 
to manufacturer’s instruction.
All the experiments were performed in stem cell 
medium in the presence of doxycycline. 
Xenograft mouse models
Animal experiments were performed in accordance 
to relevant institutional and national regulations. 2x105 
TRIPZ and TRIPZ-miR-135b GSCs, were intracranially 
injected into male NOD/SCID mice (n, 6; 4-6 weeks of 
age; CD1 NOD-/SCID mice, Charles Rives, Italy). Before 
grafting, mice were anesthetized with intraperitoneal 
injection of diazepam (2 mg/100 g) followed by 
intramuscular injection of ketamine (4 mg/100 g). The 
animal skulls were immobilized in a stereotactic head 
frame and a burr hole was made 2 mm right of the midline 
and 1 mm anterior to the coronal suture. The tip of a 10-
µl Hamilton microsyringe was placed at a depth of 3.5 
mm from the dura and the cells were slowly injected. 
Doxycycline administration in drinking water (200 µg/ml) 
started the day of injection. After 8 weeks of survival, mice 
were deeply anesthetized and transcardially perfused with 
0.1 M PBS (pH = 7.4), followed by 4% paraformaldehyde 
in 0.1 M PBS. The brain was removed, stored in 30% 
sucrose buffer overnight at 4° C and serially cryotomed 
at 20 µm on the coronal plane. Sections were collected 
in distilled water, mounted on slides, and cover-slipped 
with Eukitt. Images were obtained with a Laser Scanning 
Confocal Microscope (IX81, Olympus Inc, Melville, NY, 
USA).
The cranio-caudal extension of the brain area 
invaded by GSCs was assessed on serial coronal sections. 
Then, histological sections 120 µm apart were digitized; 
on each image, the brain region containing GSCs was 
demarcated with the cursor and its area calculated by 
using a commercially available software. To assess the 
tumor volume, each area of the infiltrated brain was 
multiplied for the distance to the consecutive digitized 
section, starting from the tumor epicentre to the cranial 
and caudal poles of the tumor, and partial volume values 
were added. The density of tumor cells was assessed by 
counting the number of GSCs in 10 non-superimposing 
high power fields across the grafted striatum. Alternate 
sections were stained with hematoxylin and eosin (H&E) 
for morphological analysis.
For intracranial implantation of U87MG GBM cells, 
male NOD-SCID mice were implanted intracranially with 
0.2 x 105 TRIPZ and TRIPZ-miR-135b U87MG cells 
resuspended in 4 µl of serum-free DMEM. Doxycycline 
administration in drinking water (200 µg/ml) started the 
day of injection. After 2 weeks of survival, mice were 
deeply anesthetized and transcardially perfused with 0.1 
M PBS (pH = 7.4), followed by 4% paraformaldehyde in 
0.1 M PBS. The brain was removed, stored in 30% sucrose 
buffer overnight at 4° C and serially cryotomed at 20 µm 
on the coronal plane. Proliferation and cell death were 
evaluated by immunostaining with Ki67 (Merck Millipore, 
Darmstadt, Germany) and terminal deoxynucleotidyl 
transferase dUTP nick-end labeling (TUNEL) assay, 
respectively. Images were obtained with a Laser Scanning 
Confocal Microscope (Flouview FV1000, Olympus Inc.).
Subcutaneous implant of T98G GBM cells was 
performed by injecting 5x105 TRIPZ and TRIPZ-miR-
135b T98G cells mixed with 0.1 ml of cold Matrigel. 
Doxycycline administration in drinking water (200 µg/
ml) started the day of injection. Matrigel implants were 
removed four weeks after grafting under magnified 
vision, stored in 30% sucrose buffer overnight at 4° C, 
and embedded in paraffin and sectioned at 3 µm for Ki67 
immunostaining.
MicroRNA target prediction
TargetScan (http://www.targetscan.org), miRanda 
(http://www.microrna.org), miRBase (http://www.mirbase.
org) and TargetMiner (http://www.isical.ac.in) were used 
for miR-135b target prediction. 
Western blot analysis
Total protein content was extracted from cells 
using RIPA buffer (20 mM Tris/HCl pH = 7.2, 200 mM 
NaCl, 1% NP40) and Protease and Phosphatase Inhibitor 
Cocktails I and II (Sigma-Aldrich). Samples were 
resolved in SDS-PAGE gels (NuPage 4-12% bis-tris Gel, 
Invitrogen). Protein expression was analyzed by standard 
western blot procedure using anti-ADAM12 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), anti-SMAD5 and 
anti-GSK3β (Cell Signaling Technology, Danvers, MA, 
USA). The Anti-β-actin monoclonal antibody was used as 
loading control (Oncogene Research Products, La Jolla, 
CA, USA). The quantitation of protein expression was 
determined after normalization to β-actin, by measuring 
the optical density of respective band blots using the 
Quantity One software (Bio-Rad Laboratories, Hercules, 
CA, USA).
Reporter assay
293T were transiently co-transfected by 
Lipofectamine 2000 (Life Technologies Corporation) 
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with 0.8 μg of firefly luciferase reporter plasmid containing 
wild-type or mutated ADAM12 3’UTRs, 40 pmol of either 
the hsa-miR135b mimic or control-mimic oligonucleotides 
(Ambion, Life technologies) and with 50 ng of Renilla 
luciferase pRL-TK as normalizer. 48 h post-transfection 
luciferase activity was quantified by Dual Luciferase 
Reporter kit (Promega Inc.) 
Gene array
Gene array was performed as previously described 
[51]. Briefly, total RNA was extracted from TRIPZ and 
TRIPZ-miR-135b GSC#83 transduced cells. RNA was 
labeled and hybridized to the Affymetrix GeneChip1.0ST 
array (Affymetrix, Santa Clara, CA, USA) following the 
manufacturer’s instructions. Hybridization values were 
normalized by the RMA method. 
Statistical analysis
Statistical analyses was performed by means of 
either “R”v3.1.2 [52] or GraphPad prism v4.0 (GraphPad 
Software, La Jolla CA, USA, www.graphpad.com). 
Statistical significance reported on the plots is the 
following: single asterisks for p < 0.05, two asterisks for p 
< 0.01 and three asterisks for p < 0.001. 
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